Appendix 4E and Annual Report 30 June 2026
Filed with ASX · · 53 pages · English
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Investor Update
- March 2026 Quarterly Activity Report & Appendix 4C
- Firebrick Secures $1.5 million via Placement
- Trading Halt
- Registration Agreement and Approval of Nasodine in Indonesia
Later from Firebrick Pharma
- Firebrick receives $293,000 R&D Tax Incentive
- Firebrick announces USA Retail Launch Plan
- Firebrick Secures $732k in Strategic Investments
- Nasodine Nasal Spray Approved in the Philippines
- New Product - Nasodine Sinus Rinse
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma